La acarbosa es un fármaco antiguo y económico para la diabetes tipo 2 que actúa en el intestino. Ralentiza las enzimas que descomponen el almidón en azúcar, de modo que llega menos glucosa a la sangre después de una comida. En la diabetes tipo 2 reduce la HbA1c de forma modesta. En el ensayo STOP-NIDDM frenó la progresión de la prediabetes a la diabetes. Su historial cardiovascular es más dispar.
El STOP-NIDDM informó de un beneficio en eventos cardíacos a partir de pocos eventos. El ensayo ACE, más grande y diseñado para probarlo, no encontró tal beneficio, aunque sí confirmó el efecto de prevención de la diabetes. La acarbosa despertó interés en la longevidad después de que prolongara la esperanza de vida en ratones. En el NIA Interventions Testing Program prolongó la vida de los ratones mucho más en machos que en hembras, y el resultado se replicó. Es un medicamento de prescripción, y sus efectos secundarios intestinales son lo que más a menudo lleva a la gente a abandonarlo.
Findings & Outcomes
What It Is
Acarbose is an oral type 2 diabetes drug in use since the 1990s. It belongs to a small class called alpha-glucosidase inhibitors. These act inside the small intestine and are barely absorbed into the body, so most of its effect and most of its side effects stay in the gut. For much of its history it was a second-line drug, used when the main problem was high blood sugar after meals. It is common in parts of East Asia, where diets are high in starch, and it is inexpensive and off-patent.
Aging researchers later took an interest for a different reason than blood sugar. A 2014 report from a program that tests drugs for lifespan in genetically diverse mice found acarbose extended their lives. That result put it on lists of candidate longevity drugs.
What It Does
In type 2 diabetes, acarbose lowers HbA1c by about 0.8 percentage points, a modest drop, weaker than metformin at usual doses. Almost all of it comes from the smaller after-meal glucose rise. In prediabetes, the STOP-NIDDM trial found it cut progression to type 2 diabetes by about a quarter over roughly three years. Type 2 diabetes is largely a diet-driven disease, built over years on refined and ultra-processed carbohydrate. In the Diabetes Prevention Program, lifestyle change alone cut progression by 58%, against 31% for metformin.
STOP-NIDDM also reported a striking drop in cardiovascular events. That result came from just a handful of events and drew heavy criticism. The ACE trial was built to settle the question, in more than 6,000 people who had coronary heart disease and prediabetes. It found no cardiovascular benefit, though it confirmed the diabetes-prevention effect.
The National Institute on Aging Interventions Testing Program runs the same test across three independent laboratories to weed out flukes. In that program, acarbose extended mouse median lifespan by about 22% in males and about 5% in females. A higher-dose study repeated the male-biased pattern. Why the effect favors males is unknown. Researchers suspect it comes from how males and females process the drug and its effects on the gut, though no mechanism is established.
No completed human study shows acarbose extends healthy lifespan or healthspan, and there is no established dose for that use.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Blood Sugar
Reduce la HbA1c en aproximadamente 0.8 puntos porcentuales en la diabetes tipo 2
La acarbosa reduce la glucemia a largo plazo en la diabetes tipo 2 en algo menos de un punto porcentual de HbA1c, un descenso modesto.
En una revisión Cochrane de los inhibidores de la alfa-glucosidasa en diabetes tipo 2, la acarbosa redujo la HbA1c en aproximadamente 0.8 puntos porcentuales frente a placebo, una reducción menor que la que suele producir la metformina, actuando principalmente al atenuar el aumento de la glucosa posprandial. Measured in: Pooled randomized trials of acarbose and other alpha-glucosidase inhibitors in adults with type 2 diabetes.. Los ensayos combinados variaron en dosis, duración y dieta, y muchos fueron de corta duración; el efecto glucémico es menor que el de los fármacos de primera línea.
The study · 1
Van de Laar et al., alpha-glucosidase inhibitors for type 2 diabetes mellitus (Cochrane review) · Cochrane Database Syst Rev 2005
Redujo la progresión de prediabetes a diabetes en aproximadamente un 25 % en 3.3 años (STOP-NIDDM)
En personas con prediabetes, la acarbosa redujo la tasa de desarrollo de diabetes tipo 2 en aproximadamente una cuarta parte a lo largo de unos tres años.
En el ensayo STOP-NIDDM, la acarbosa redujo el riesgo relativo de progresar de la intolerancia a la glucosa a la diabetes tipo 2 en aproximadamente un 25 % (hazard ratio 0.75) durante una media de 3.3 años frente a placebo. Measured in: 1,429 adults with impaired glucose tolerance, randomized to acarbose or placebo, mean follow-up 3.3 years.. Una alta tasa de abandonos, en gran parte por efectos secundarios gastrointestinales, complicó el análisis, y algunos diagnósticos de diabetes aparecieron poco después de suspender la acarbosa.
The study · 1
Chiasson et al., acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial · Lancet 2002
El mismo ensayo ACE redujo la nueva diabetes en aproximadamente un 18 %
El mismo gran ensayo que no encontró beneficio cardíaco sí confirmó que la acarbosa redujo la aparición de diabetes.
En el mismo ensayo ACE, la acarbosa redujo la incidencia de nueva diabetes tipo 2 en aproximadamente un 18 % (rate ratio 0.82) frente a placebo, confirmando un efecto de prevención de la diabetes de magnitud similar al de STOP-NIDDM. Measured in: 6,522 Chinese adults with coronary heart disease and impaired glucose tolerance, median follow-up 5 years.. La reducción absoluta fue modesta y esta población ya padecía enfermedad coronaria, por lo que el beneficio de prevención debe interpretarse junto con la tolerabilidad del fármaco.
The study · 1
Holman et al., effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE) · Lancet Diabetes Endocrinol 2017
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Heart And Vascular
Sin reducción de los eventos cardiovasculares en el ensayo ACE, de mayor tamaño (hazard ratio 0.98)
En un gran ensayo diseñado específicamente para comprobarlo, la acarbosa no redujo la tasa de infartos, accidentes cerebrovasculares ni muerte cardiovascular.
En el ensayo ACE, la acarbosa no redujo el criterio de valoración compuesto primario de eventos cardiovasculares mayores (hazard ratio 0.98) en adultos chinos con enfermedad coronaria e intolerancia a la glucosa durante una mediana de 5 años. Measured in: 6,522 Chinese adults with coronary heart disease and impaired glucose tolerance, randomized to acarbose or placebo, median 5 years.. El ensayo se realizó en una población de Asia oriental con enfermedad coronaria establecida, por lo que no descarta un efecto diferente en otros grupos, pero contradice directamente la señal cardiovascular anterior.
The study · 1
Holman et al., effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE) · Lancet Diabetes Endocrinol 2017
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
STOP-NIDDM sugirió un 49 % menos de eventos cardiovasculares, a partir de muy pocos eventos
Un ensayo temprano sugirió que la acarbosa podría reducir los eventos cardíacos en la prediabetes, pero la señal provenía de muy pocos eventos y no era convincente por sí sola.
Un análisis secundario de STOP-NIDDM informó que la acarbosa se asoció con una reducción relativa del 49 % en los eventos cardiovasculares y con menos infartos de miocardio, pero el hallazgo se basaba en un pequeño número de eventos y fue ampliamente criticado. Measured in: 1,429 adults with impaired glucose tolerance in STOP-NIDDM; cardiovascular events were a secondary endpoint with few total events.. El resultado cardiovascular era un criterio de valoración secundario basado en un puñado de eventos (por ejemplo, uno frente a doce infartos de miocardio), y un ensayo específico posterior no lo confirmó.
The study · 1
Longevity And Mortality
Prolongó la esperanza de vida media en aproximadamente un 22 % en ratones machos, y en aproximadamente un 5 % en las hembras
La acarbosa hizo que los ratones vivieran más tiempo, con un efecto mucho mayor en los machos que en las hembras, en un estudio riguroso multicéntrico.
En el NIA Interventions Testing Program, la acarbosa añadida a la dieta desde los 4 meses de edad (adultez temprana) prolongó la esperanza de vida media en aproximadamente un 22 % en ratones machos genéticamente diversos y en aproximadamente un 5 % en las hembras, un efecto sesgado por sexo observado en tres laboratorios independientes. Se trata de un resultado animal en ratones, y la marcada diferencia por sexo no tiene explicación; no puede trasladarse directamente a las personas.
The study · 1
Harrison et al., acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males · Aging Cell 2014
Las dosis más altas elevaron la esperanza de vida de los ratones machos en un 16 % o un 17 %, en las hembras un 4 % o un 5 %
Un segundo estudio en ratones con dosis más altas volvió a prolongar la esperanza de vida de los machos más que la de las hembras, en aproximadamente un 16 % o un 17 % en los machos, y siguió funcionando cuando el tratamiento comenzaba más tarde en la vida.
Un estudio de seguimiento del Interventions Testing Program evaluó la acarbosa en tres dosis y encontró que las dos dosis más altas aumentaron la esperanza de vida media de los ratones machos en un 16 % o un 17 %, y la de las hembras en un 4 % o un 5 %, replicando el beneficio sesgado hacia los machos incluso cuando el tratamiento comenzaba más tarde en la vida. Esto sigue siendo un resultado en ratones; la diferencia por sexo replicada y la dependencia de una dosificación dietética continua limitan hasta qué punto puede trasladarse a los humanos.
The study · 1
Harrison et al., acarbose improves health and lifespan in aging HET3 mice · Aging Cell 2019
How it works
Fermentación intestinal y ácidos grasos de cadena corta: un mecanismo de longevidad propuesto en ratones
En ratones, la acarbosa cambió las bacterias intestinales y aumentó los productos útiles de la fermentación, y esos cambios se alinearon con cuánto más vivieron los ratones.
En ratones, la acarbosa cambió la composición del microbioma intestinal y elevó los niveles de ácidos grasos de cadena corta como el butirato y el propionato, y el grado de estos cambios se correlacionó con la prolongación de la esperanza de vida, lo que sugiere que la fermentación colónica es parte del mecanismo. Esto es una correlación dentro de estudios en ratones entre los cambios del microbioma y la esperanza de vida, no una prueba de que los ácidos grasos de cadena corta causen el efecto de longevidad.
The study · 1
Smith et al., changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice · BMC Microbiol 2019
Anatomy
1A gut-acting drug
Acarbose is an alpha-glucosidase inhibitor, taken by mouth with the first bite of a meal, so it is in place as the carbohydrate arrives.
2How it blunts the sugar spike
Enzymes in the intestinal wall normally break starch and sucrose into glucose so it can be absorbed. Acarbose slows those enzymes, so carbohydrate is digested more gradually and glucose enters the blood more slowly. The result is a lower, flatter rise in blood sugar after a meal. That is where the drug does most of its work on blood sugar.
3The carbohydrate that reaches the colon
Because some carbohydrate is not broken down in the small intestine, more of it passes into the colon, where gut bacteria ferment it. That fermentation produces short-chain fatty acids such as butyrate, and it also produces the gas that is its main side effect. The same fermentation is one of the mechanisms researchers suspect in the animal longevity findings.
How to Approach It
These steps run from the foundations that help anyone down to the animal findings still confined to the lab.
Eating fewer refined carbohydrates, walking after meals, and building muscle that takes up glucose all lower the same after-meal glucose rise the drug targets. These foundations carry far stronger evidence for metabolic health and healthy aging than any longevity drug. See [resistance training](/go/integrative/practice/resistance-training) for holding muscle with age.
The diabetes and prediabetes evidence above is the solid part: acarbose suits people whose blood sugar spikes mainly after meals, and it is inexpensive. Whether it fits your blood sugar, your other medicines, and your tolerance for its gut effects is a conversation with a prescriber.
The animal findings are what put acarbose on longevity forums, and human data will decide whether they carry over. Following that research as it appears is free. The drug itself is a prescription decision, and a clinician can weigh it against the gut side effects.
Go Deeper
- The biology of aging: where nutrient handling and the gut sit among the hallmarks of aging, and how to read an animal drug result against the human evidence.
- Insulin and glucose handling: the metabolic system acarbose acts on, and why flattening the after-meal glucose rise matters.
- Metformin: the other cheap diabetes drug at the center of the longevity question, with a stronger glycemic record and the same gap between hint and proof.
- Berberine: the plant compound often sold as a natural blood-sugar agent, and what its evidence shows.
The Chinese Medicine View
Acarbose comes from modern pharmacology, so the tradition never named it. But it acts on ground Chinese medicine mapped long ago: digestion. The Spleen and Stomach, in this framework, govern the transformation and transport of food into usable substance. When rich or excessive eating overwhelms that work, the tradition describes food stagnating and turning to Dampness and Phlegm. Those patterns are often mapped onto the modern picture of insulin resistance and the excess weight of type 2 diabetes. A drug that slows the breakdown of a heavy starchy meal works in that same territory.
The tradition points in two directions here. Yang Sheng advises eating in moderation and not overwhelming the digestion: advice that lines up with a drug meant to ease a large carbohydrate load. Yet the same framework holds that the Spleen dislikes Dampness and stagnation. In these terms, a drug that leaves carbohydrate to ferment and produce gas creates the same fullness the tradition tries to relieve. That the drug's most common real-world complaint is bloating is an ironic echo, not evidence that the Damp-Phlegm model predicted it. Its place in type 2 diabetes care comes from the randomized trials above.
Cautions
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Los gases, la hinchazón y la diarrea son la principal razón por la que las personas dejan la acarbosa
En los ensayos combinados en la revisión Cochrane, la acarbosa causó sustancialmente más flatulencia, hinchazón y diarrea que el placebo, y estos efectos gastrointestinales fueron la principal razón por la que los participantes dejaron el fármaco. Los efectos secundarios están relacionados con la dosis y a menudo se alivian con un aumento lento, pero impulsan altas tasas de abandono y complicaron los ensayos.Van de Laar et al., alpha-glucosidase inhibitors for type 2 diabetes mellitus (Cochrane review)
A prescription drug, and the decision sits with a clinician
Acarbose is a prescription medicine. Whether it fits, at what dose, and how fast to build up depends on your blood sugar, your digestion, your other conditions and other medicines. Starting, changing or stopping it belongs with a prescriber. No safe general dose exists for a healthy person outside diabetes care.
Gas, bloating and diarrhea are the usual limit
Because acarbose leaves carbohydrate to ferment in the colon, flatulence, bloating, abdominal discomfort and diarrhea are common, especially early and after high-starch meals. These are the main reason people stop the drug. They often ease with a slow dose increase and tend to lessen over weeks, but for many people they are the deciding factor.
Bowel and digestive conditions are a boundary
Acarbose is not appropriate in inflammatory bowel disease, significant intestinal obstruction, or malabsorption disorders. A drug that increases fermentation and gas can worsen them. Anyone with a chronic gut condition needs a prescriber to judge whether it is safe at all.
Low blood sugar must be treated with glucose, not table sugar
On its own acarbose rarely causes low blood sugar, but combined with insulin or a sulfonylurea it can. If that happens, the low must be treated with glucose (dextrose). Ordinary table sugar or fruit will not work fast enough, because acarbose slows the breakdown of table sugar into the glucose the body uses quickly. This is a specific safety point a prescriber will explain.
Liver enzymes at higher doses
At higher doses acarbose has been associated with reversible rises in liver enzymes, one reason the dose is capped and monitored. This is a matter for the prescriber, and it resolves when the drug is reduced or stopped.
Off-label use pushes toward the doses with the most side effects
Any use of acarbose for aging, outside diabetes care, is off-label and unstudied, and interest in a bigger effect tends to push toward higher doses. Higher doses are where flatulence and diarrhea are worst and where the reversible liver-enzyme rises appear. That trade-off is what a person would actually be choosing.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
Does acarbose extend lifespan?
In mice, it does, and the finding is unusually solid. In the NIA Interventions Testing Program acarbose extended median lifespan in genetically diverse mice. The effect was much larger in males than females, and it was replicated at higher doses. In people, it has not been shown to extend lifespan or healthspan. No completed human longevity trial exists, so the accurate summary is a striking and replicated animal result with no human confirmation yet.
Why is the effect stronger in male mice?
That sex difference is not fully explained. Across the Interventions Testing Program, acarbose extended male mouse lifespan far more than female, and a later higher-dose study confirmed the pattern. Researchers suspect it involves differences in how males and females metabolize the drug and how it acts in the gut. The mechanism behind the sex gap is not established. It is one more reason the mouse result cannot be read straight across to people of either sex.
Does acarbose protect the heart?
The better evidence says no. The idea comes from the STOP-NIDDM trial, which reported fewer cardiovascular events. That result rested on a small number of events in a secondary analysis and was widely questioned. The ACE trial was designed to test it directly in more than six thousand people with established heart disease and prediabetes. In that trial acarbose produced no reduction in cardiovascular events, while confirming that it reduced the onset of diabetes.
What are the main side effects?
They are almost all digestive. Flatulence, bloating, abdominal discomfort and diarrhea are common, because the drug leaves carbohydrate to ferment in the colon, and they are the usual reason people stop taking it. They tend to be worst early and after high-starch meals and often ease with a slow dose increase. At higher doses acarbose has also been linked to reversible rises in liver enzymes. That is part of why the dose is capped and monitored.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 9 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.